1. Gioffredi A, Maritati F, Oliva E, Buzio C. Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol, 2014, (5): 549.
[2]
2. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum, 1994, 37(2): 187-192.
[3]
3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum, 2013, 65(1): 1-11.
[4]
4. Woolnough K, Wardlaw AJ. Eosinophilia in Pulmonary Disorders. Immunol Allergy Clin North Am, 2015, 35(3): 477-492.
[5]
5. Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun, 2014, 48-49: 99-103.
[6]
6. Mahr A, Moosig F, Neumann T, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol, 2014, 26(1): 16-23.
[7]
7. Santos YA, Silva BR, Lira PN, et al. Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes. Respir Med Case Rep, 2017, 21: 1-6.
[8]
8. Parent ME, Larue S, Ellezam B. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) presenting as diffuse myositis. BMC Musculoskelet Disord, 2014, 15: 388.
[9]
9. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum, 1990, 33(8): 1094-1100.
[10]
10. Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term follow up of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum, 2013, 65(1): 270-281.
[11]
11. Guillevin L, Pagnoux C, Seror R, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vas-culitides based on the French Vasculitis Study Group(FVSG) cohort. Medicine (Baltimore), 2011, 90(1): 19-27.
[12]
12. Lefèvre G, Ackermann F, Kahn JE. Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: Eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome?. Autoimmun Rev, 2017, 16(2): 208-209.
15. Agarwal R, Sehgal IS, Dhooria S, et al. Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. Expert Rev Respir Med, 2016, 10(12): 1317-1334.
[16]
16. Greenberger PA, Bush RK, Demain JG, et al. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract, 2014, 2(6): 703-708.
[17]
17. Opri？？ R, Opri？？ B, Berceanu D, et al. Overview of IgG4-related disease. J Med Life, 2017, 10(4): 203-207.
[18]
18. ？en N, Ayd？n Tufan M, Y？ld？z R, et al. Granulomatous polyangiitis (Wegener granulomatosis): clinical findings and results of long-term follow-up. Tuberk Toraks, 2016, 64(3): 223-229.
[19]
19. Pagnoux C, Groh M. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Expert Rev Clin Immunol, 2016, 12(10): 1059-1067.
